Genethera Stock Number Of Shares Shorted
GTHR Stock | USD 0.0001 0.00 0.00% |
GeneThera fundamentals help investors to digest information that contributes to GeneThera's financial success or failures. It also enables traders to predict the movement of GeneThera Pink Sheet. The fundamental analysis module provides a way to measure GeneThera's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GeneThera pink sheet.
GeneThera |
GeneThera Company Number Of Shares Shorted Analysis
GeneThera's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Competition |
Based on the recorded statements, GeneThera has 0.0 of outstending shares currently sold short by investors. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The number of shares shorted for all United States stocks is 100.0% higher than that of the company.
GeneThera Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GeneThera's direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of GeneThera could also be used in its relative valuation, which is a method of valuing GeneThera by comparing valuation metrics of similar companies.GeneThera is currently under evaluation in number of shares shorted category among its peers.
GeneThera Fundamentals
Return On Asset | -95.38 | |||
Current Valuation | 1.44 M | |||
Shares Outstanding | 35.33 M | |||
Shares Owned By Insiders | 17.99 % | |||
Price To Earning | (0.17) X | |||
EBITDA | (1 M) | |||
Net Income | (1.01 M) | |||
Cash And Equivalents | 140.1 K | |||
Total Debt | 806.87 K | |||
Book Value Per Share | (0.24) X | |||
Cash Flow From Operations | (8.57 K) | |||
Earnings Per Share | (0.03) X | |||
Beta | 0.89 | |||
Market Capitalization | 533.53 K | |||
Total Asset | 6.3 K | |||
Retained Earnings | (25.59 M) | |||
Working Capital | (7.03 M) | |||
Current Asset | 55 K | |||
Current Liabilities | 7.08 M | |||
Net Asset | 6.3 K |
About GeneThera Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GeneThera's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GeneThera using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GeneThera based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for GeneThera Pink Sheet Analysis
When running GeneThera's price analysis, check to measure GeneThera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneThera is operating at the current time. Most of GeneThera's value examination focuses on studying past and present price action to predict the probability of GeneThera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneThera's price. Additionally, you may evaluate how the addition of GeneThera to your portfolios can decrease your overall portfolio volatility.